1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6B3BC4E86BD1BB0148525770000253EE5
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/maintain-corporate-affairs-function-insights-for-optimizing-structure-operations
18
19
20172.70.178.154
21
22
23527255.sherryhk.tech
24/bestp/domrep.nsf
25BMR




» Products & Services » » Quality, Compliance and Regulatory » Corporate Affairs

Corporate Affairs Excellence: Optimizing Group Structure & Operations

ID: PSM-251


Features:

18 Info Graphics

9 Data Graphics

68 Metrics

3 Narratives


Pages: 38


Published: Pre-2019


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
In this dynamic political, economic and social environment, the Corporate Affairs function is crucial to any biopharmaceutical company's economic health and survival. Top companies recognize the value of Corporate Affairs and see it as a strategic tool -- building company reputation and brand, as well as forging strong corporate relationships with external stakeholders. A strong Corporate Affairs function can drive corporate success.

This report
provides benchmarks to identify key Corporate Affairs resources, issues, services and priorities across the bio-pharmaceutical and medical device industry and other regulated business sectors. This report examines performance excellence by probing the most critical Corporate Affairs specialty groups.

Also, this study presents different organizational models for Corporate Affairs and current trends in staffing and budgets for these groups as well.

Corporate Affairs leaders can use this research to compare their organizational structure and resourcing with those of leading organizations.

Industries Profiled:
Pharmaceutical; Biotech; Health Care; Transportation; Service; Chemical; Medical Device; Insurance; Utilities


Companies Profiled:
Abbott Laboratories; GlaxoSmithKline; Amgen; Astellas Pharma; Inc.; Astra Zeneca; Boehringer Ingelheim; ConvaTec; DRI; Eisai; Eli Lilly and Company; Emirates; Genentech; Genomic Health; Genzyme; Intas Pharma; MDS Nordion; Medtronic; Merck Sharp Dohme Turkey; MetLife; MSD; National Grid; Novo Nordisk; Pfizer; Purdue Pharma LP; Roche Diagnostics Diabetes Care; Solvay; Stiefel; UCB; W. R. Grace & Co.

Study Snapshot

This multi-industry benchmarking study is aimed at examining key trends that drive structural changes in corporate affairs and variations in service level priorities. This study comprises valuable metrics and actionable insights that can be used to compare current practices at organizations with best-in-class approaches in maintaining a high-performing Corporate Affairs function.

This benchmarking research included 28 corporate affairs executives and managers at 27 leading bio-pharmaceutical, healthcare and non-healthcare companies.

Field interviews and study analysis produced many observations and benchmark findings. Key study insights reflect the inter-related evolution of a company’s commercial structure and indicate when organizations embrace organizational change –such as business unit structures -to support their growth and profitability

Key Findings

Centralized Structures Are Favored for Corporate Affairs Groups:

    Nearly 60% of benchmark partners described their Corporate Affairs / Public Affairs group structures as “centralized.”
  • Product Portfolio Characteristics Influence Corporate Affairs Focus:
    Optimizing corporate affairs effectiveness is an evolutionary process. It reflects the ongoing task of balancing one’s product portfolio complexity with issues of corporate size and scale andalso with issues of geographic reach.
Table of Contents

PROJECT BLUEPRINT 3
EXECUTIVE SUMMARY: BENCHMARK INSIGHTS &
RESEARCH PARTICIPANTS 4
Corporate Affairs Benchmark Research Participants 5
Participants’ Job Titles Typically Director or Above 6
Functional Perspectives Circumscribe Corporate Affairs 7
Key Insights & Observations from Analysis-1 8
Key Insights & Observations from Analysis-2 9
COMMERCIAL STRUCTURES:
TRENDS THAT DRIVE EVOLUTION OF CORPORATE AFFAIRS 10
Study Attracted Diverse Mix of Companies by Size 11
Participants’ Revenues Range from $3B to $55B 12
Hybrid Structure Most Common of Approaches 13
B.U. Structure based Upon Geography, Therapeutic Areas
& Lines of Business 14
Corporate Affairs- Business Unit Structure 15
CORPORATE AFFAIRS GROUP STRUCTURES:
KEY TRENDS AND DRIVERS OF SUB-GROUP EVOLUTION 16
Corporate Affairs Leadership Often Set at VP-Level 17
Corporate/Public Affairs Head Often Reports to C- Level 18
Centralized Structures Favored for Corporate Affairs 19
CORPORATE AFFAIRS GROUP MODELS AND STRUCTURES 20
Corporate Affairs Group Structure-Big Pharma Decentralized Approach-A 21
Corporate Affairs Group Structure-Big Pharma Decentralized Approach-B 22
Corporate Affairs Group Structure-Big Pharma Decentralized Approach-C 23
Corporate Affairs Group Structure-Big Pharma Decentralized Approach-D 24
Corporate Affairs Group Structure-Large Cap Healthcare
Company- Hybrid Approach-E 25
Company Affairs Group Structure- Mid Cap Pharma Hybrid Approach- A 26
Company Affairs Group Structure-
Mid Cap Pharma- Decentralized Approach-B 27
Corporate Affairs Group Structure-
Mid Cap Pharma Company- Centralized Approach-C 28
Corporate Affairs Structure-
Mid-Cap Medical Device Company- Decentralized Approach- D 29
Corporate Affairs Group Structure- Mid-Cap
Non- Pharma Company- centralized Approach- E 30
Corporate Affairs Group Structure- Mid-Cap Medical Device Company- Centralized Approach- F 31
Corporate Affairs Group Structure- Mid Cap Non- Healthcare Company- Centralized Approach- G 32
CORPORATE AFFAIRS GROUP SERVICES:
KEY TRENDS IN SERVICE LEVELS & PRIORITIES 33
Corporate Affairs Head Oversees Various Functions 34
Corporate Size & Geographic Span Direct CA Priorities 35
Product Portfolio Characteristics influence Corporate Affairs Focus 36
Corporate Affairs Can Protect Produce & Corporate Interests 37
About Best Practices, LLC 38

List of Charts & Exhibits

Estimated total number of employees and sales revenues for benchmarked companies for the last completed fiscal year.
  • Percentage of companies with different types of commercial operating structures
  • Percentage of companies with different types of business unit structures
  • Percentage of Corporate/Public affairs head reporting to each organizational level
  • Different types of Corporate Affairs group structures
  • Corporate Affairs group services scope
  • Estimated the total number of blockbuster products and smaller brands supported by the Corporate / Public Affairs group